Parkside Scientific, Inc.
Parkside Scientific, Inc.

Parkside Scientific Inc. creates novel small-molecule drug therapies for cancers and inflammatory diseases based on pioneering epigenetic work of our Founder/Chief Scientist Ming-Ming Zhou, PhD, who continues to Chair the Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai.  With strong IP/proprietary knowledge of epigenetic control mechanisms of gene transcription, Parkside is pursuing breakthrough platform technology aimed at a variety of intractable cancers (e.g., TNBC, prostate) and inflammatory diseases (IBD, Diabetes, Obesity).  Our most advanced compound targets Triple-Negative Breast Cancer (TNBC), which has no drug therapy (other than chemo) and a potential US/ China/EU market estimated at over $5 billion annually.